您现在的位置: 首页   -  产品中心   -  免疫学   -   抗体
Biotinylated PD-L1 Avi&His Tag Protein, Human

Biotinylated PD-L1 Avi&His Tag Protein, Human

货号: UA010541
价格: 2450
规格: 25μg
介绍: -
其他: -
产品规格
  • 物种

    Human
  • 抗原名称

    PD-L1
  • 分子别名

    PD-L1, CD274, B7-H1, PDCD1L1, PDCD1LG1
  • Accession

    Q9NZQ7
  • 表达序列

    Phe19-Arg238, with C-terminal Avi&His Tag FTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERGGGSGLNDIFEAQKIEWHEHHHHHHHH

  • 表达宿主

    HEK293
  • 分子量

    33-40kDa
  • 纯度

    >95% by SDS-PAGE
  • 内毒素含量

    <0.1EU/μg
  • 标记

    Biotin
  • 标签

    Avi Tag, His Tag
  • 性状

    Lyophilized Powder
  • 缓冲体系

    PBS, pH7.4
  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.
    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.
    · Please avoid repeated freeze-thaw cycles.
  • 文献引用

    1. Joel Sunshine, Janis M Taube: PD-1/PD-L1 inhibitors, Current Opinion in Pharmacology, Volume 23, August 2015, Pages 32-38.

  • 稀释度

背景介绍
  • PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PDL1 is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. PD-L1 provides a molecular stop signal to the adaptive immune system helping to distinguish between self and foreign antigens. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Many cancers exhibit upregulated PD-L1 protein expression, and several cancers with high levels of PD-L1 have been associated with increased tumor aggressiveness and poor prognosis. Using new therapeutics that block the PD-L1:PD-1 interaction has proven successful in the clinic for many cancer types and has sparked great interest in the field of cancer immunotherapy.

  • 电泳JSON

    • 1μg (R: reducing conditions, N: non-reducing conditions).

  • ELISA

    • Immobilized Biotinylated PD-L1 Avi&His Tag, Human (Cat. No. UA010541) at 2 μg/mL on Streptavidin precoated (0.5μg/well) plate, can bind PD-1 Fc Chimera, Human (Cat. No. UA010002) with EC50 of 1.21-1.70 ng/ml.